达格列净联合门冬胰岛素30注射液对新诊断2型糖尿病患者血糖控制及体质量指数的影响被引量：7

导出

摘要目的研究达格列净联合门冬胰岛素30注射液对新诊断2型糖尿病(T2DM)患者血糖控制及体质量指数的影响.方法选取我院86例新诊断T2DM患者,随机数字表法分为两组,各43例.对照组采用门冬胰岛素30注射液治疗,研究组于对照组基础上加用达格列净治疗.对比两组治疗前后血糖指标[糖化血红蛋白(HbA1c)、空腹血糖(FPG)]及体质量指数(BMI).结果治疗3个月后,研究组HbA1c、FPG水平及BMI均低于对照组(P<0.05).结论采用达格列净联合门冬胰岛素30注射液治疗新诊断T2DM患者,能显著提高血糖控制效果,改善患者体质量指数.

作者仓海忠

机构地区河南省中牟县第二人民医院

出处《首都食品与医药》 2020年第13期87-87,共1页 Capital Food Medicine

关键词 2型糖尿病达格列净门冬胰岛素30注射液

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献2

1章丹,曾婷婷,徐海燕,卢晔芬.达格列净联合二甲双胍治疗2型糖尿病疗效观察[J].药物流行病学杂志,2018,27(10):637-639. 被引量：36
2张波,杨文英.钠-葡萄糖共转运蛋白2抑制剂（SGLT2i）在治疗2型糖尿病中的有效性和安全性[J].中华内分泌代谢杂志,2016,32(2):171-176. 被引量：35

二级参考文献53

1Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014 [ N/OL]. Available at: http://www, cdc. gov/diabetes/pubs/ statsreport 14/national-diabetes-report -web. pdf.
2Yu Xu, LiminWang, et al. Prevalence and Control of Diabetes in Chinese Adults[J]. JAMA, 2013,310(9) :948-959.
3International Diabetes Federation. IDF Diabetes Atlas update poster, 6th ed [ M ]. Brussels, Belgium: International Diabetes Federation, 2014.
4American Diabetes Association. Standards of medical care in diabetes- 2015 [ J ]. Diabetes Care, 2015,38 ( Suppl 1 ) : S1 -$90.
5Garber A J, Abrahamson MJ, et al. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement-executive summary [ J ]. Endocr Pract, 2013,19 (3) :536-557.
6Stark Casagrande S, Fradkin JE, et al. The prevalence of meeting A1 C, blood pressure, and LDL goals among people with diabetes, 1988-2010 [J]. Diabetes Care, 2013,36(8) :2271-2279.
7Ali MK, McKeever Bullard K, et al. Achievement of goals in U. S. diabetes care, 1999-2010[J]. N Engl J Med, 2013,368 ( 17 ) : 1613- 1624.
8Vivian EM. Sodium-glucose co-transporter 2 ( SGLT2 ) inhibitors : a growing class of antidiabetic agents[J]. Drugs in Context, 2014,3 : 212264.
9Hasan F, Alsabli M, Gerieh J. SGLT2 inhibitors in the treatment of type 2 diabetes[J]. Diabetes Res CIin Pratt, 2014,104:297-322.
10Kalra S. Sodium Glucose Co-Transporter-2 ( SGLT2 ) Inhibitors: AReview of Their Basic and Clinical Pharmacology[J]. Diabetes Ther, 2014,5(2) :355-366.